Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Calcitriol was discontinued on day −1 and reinitiated in response to hypocalcemia or increasing calcium requirements in 7 participants with a mean dose of 0.25±0.24 mcg/day by day 5, less than half the mean pre-admission dose of 0.68±0.43 mcg/day.

Source: Calcium and calcitriol intake were lower than baseline on encaleret. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Open-label reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

PTH-Independent CaSR Inhibition with the Oral Calcilytic Encaleret Improves Calcium Homeostasis in Post-Surgical Hypoparathyroidism: A Phase 2 Open-Label Proof-of-Concept Trial

Source: Article title.

Patients were excluded from the treatment phase of the study if they had severe symptoms despite normal or low-normal blood calcium levels, hypocalcemic seizures within the previous 3 months, treatment with any PTH analogs within the previous 3 months, 25OH-vitamin D <25 ng/mL or >60 ng/mL, or any risk factors for osteosarcoma.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

PTH-Independent CaSR Inhibition with the Oral Calcilytic Encaleret Improves Calcium Homeostasis in Post-Surgical Hypoparathyroidism: A Phase 2 Open-Label Proof-of-Concept Trial

Study design awaiting verification · Research Square · 2026

Original publication title

PTH-Independent CaSR Inhibition with the Oral Calcilytic Encaleret Improves Calcium Homeostasis in Post-Surgical Hypoparathyroidism: A Phase 2 Open-Label Proof-of-Concept Trial

Iris Ruth Hartley; Rachel Ilana Gafni; Xiaobai Li; Ashna Grover; Elizabeth A. Ferguson; Casey A. Moore; Karen A. Pozo; Kimberly T. Ampuero; Ananth V. Sridhar; Arun S. Mathew PharmD; Mary Scott Roberts; Scott H. Adler; Edward F. Nemeth; Kelly L. Roszko; Michael T. Collins

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The calcium-sensing receptor (CaSR) maintains calcium homeostasis by regulating parathyroid hormone (PTH) secretion and directly modulating renal calcium reabsorption. In the kidney, PTH and renal CaSR signaling exert opposing effects on tubular calcium reabsorption and urinary calcium excretion, complicating efforts to define their independent contributions to overall calcium regulation. To examine the PTH-independent effects of CaSR inhibition on renal calcium handling, we administered a calcilytic (CaSR antagonist) to individuals with post-surgical hypoparathyroidism (PSH).

In this open-label, phase 2, proof-of-concept study (NCT0573515), ten adults (26-69y) with chronic PSH were orally administered the calcilytic encaleret for up to 5 days. Calcitriol was discontinued one day prior, and calcium and calcitriol were individually titrated based on blood calcium. Mean fractional excretion of calcium (FECa) decreased by 39±29% (p=0.002) by end of treatment.

Albumin-corrected serum calcium increased from 8.5±0.3 mg/dL (mean±SD, normal 8.4-10.2) at time 0 to 9.2±0.6 (p=0.002) at 48 hours while urinary calcium decreased from 405±200 mg/day (m:<250; f:<350) to 180±100 (p=0.0005). Although mean intact PTH increased modestly 30 minutes after the first encaleret dose (7.3±3.1 pg/mL to 12.3±7.9 pg/mL; normal 15-65; p=0.008), levels rapidly returned to baseline without further excursions for the remainder of the study. No serious adverse events (AEs) were reported. Transient mild hypercalcemia and headache in 1 participant were the only treatment-related AEs.

In PSH, encaleret reduced urinary Ca and increased serum Ca, demonstrating the PTH-independent role of CaSR signaling in renal calcium handling and supporting further study of encaleret as an oral treatment for patients with PSH.

Authors’ abstract

The calcium-sensing receptor (CaSR) maintains calcium homeostasis by regulating parathyroid hormone (PTH) secretion and directly modulating renal calcium reabsorption. In the kidney, PTH and renal CaSR signaling exert opposing effects on tubular calcium reabsorption and urinary calcium excretion, complicating efforts to define their independent contributions to overall calcium regulation. To examine the PTH-independent effects of CaSR inhibition on renal calcium handling, we administered a calcilytic (CaSR antagonist) to individuals with post-surgical hypoparathyroidism (PSH).

In this open-label, phase 2, proof-of-concept study (NCT0573515), ten adults (26-69y) with chronic PSH were orally administered the calcilytic encaleret for up to 5 days. Calcitriol was discontinued one day prior, and calcium and calcitriol were individually titrated based on blood calcium. Mean fractional excretion of calcium (FECa) decreased by 39±29% (p=0.002) by end of treatment.

Albumin-corrected serum calcium increased from 8.5±0.3 mg/dL (mean±SD, normal 8.4-10.2) at time 0 to 9.2±0.6 (p=0.002) at 48 hours while urinary calcium decreased from 405±200 mg/day (m:<250; f:<350) to 180±100 (p=0.0005). Although mean intact PTH increased modestly 30 minutes after the first encaleret dose (7.3±3.1 pg/mL to 12.3±7.9 pg/mL; normal 15-65; p=0.008), levels rapidly returned to baseline without further excursions for the remainder of the study. No serious adverse events (AEs) were reported. Transient mild hypercalcemia and headache in 1 participant were the only treatment-related AEs.

In PSH, encaleret reduced urinary Ca and increased serum Ca, demonstrating the PTH-independent role of CaSR signaling in renal calcium handling and supporting further study of encaleret as an oral treatment for patients with PSH.

Publication and source details

Original title: PTH-Independent CaSR Inhibition with the Oral Calcilytic Encaleret Improves Calcium Homeostasis in Post-Surgical Hypoparathyroidism: A Phase 2 Open-Label Proof-of-Concept Trial

Iris Ruth Hartley; Rachel Ilana Gafni; Xiaobai Li; Ashna Grover; Elizabeth A. Ferguson; Casey A. Moore; Karen A. Pozo; Kimberly T. Ampuero; Ananth V. Sridhar; Arun S. Mathew PharmD; Mary Scott Roberts; Scott H. Adler; Edward F. Nemeth; Kelly L. Roszko; Michael T. Collins

Research Square · 2026

Corresponding author contact Iris Hartley, Address: 30 Convent Ave Rm 218 Bethesda, MD 20892, iris.hartley@nih.gov; Fax: 301-480-3037

Contributions

M.C. contributed to conceptualization, methodology, and early supervision of the study while employed at the NIDCR. Following departure from NIH and subsequent engagement as a consultant for Calcilytix Therapeutics, his contributions were limited to manuscript review and comments.

https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:46:50.028783+00:00

DOI: 10.21203/rs.3.rs-9499053/v1 · PMC13193124